IHM
Iguana Healthcare Management Portfolio holdings
AUM
$133M
This Quarter Return
+27.08%
1 Year Return
+45.66%
3 Year Return
+127.07%
5 Year Return
–
10 Year Return
–
AUM
$481M
AUM Growth
+$481M
(+121%)
Cap. Flow
+$232M
Cap. Flow
% of AUM
48.2%
Top 10 Holdings %
Top 10 Hldgs %
40.64%
Holding
93
New
17
Increased
41
Reduced
5
Closed
21
Top Buys
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$20.2M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$18.4M |
| 3 |
Biogen
BIIB
|
$13.3M |
| 4 |
MDCO
Medicines Co
MDCO
|
$12.8M |
| 5 |
Amgen
AMGN
|
$12.5M |
Top Sells
| 1 |
Baxter International
BAX
|
$6.11M |
| 2 |
HCA Healthcare
HCA
|
$3.85M |
| 3 |
Illumina
ILMN
|
$3.51M |
| 4 |
Elevance Health
ELV
|
$2.51M |
| 5 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$2.1M |
Sector Composition
| 1 | Healthcare | 85.28% |
| 2 | Energy | 1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
XLRN
51
DELISTED
Acceleron Pharma Inc.
XLRN
| $2.53M | 0.45% |
70,000
+20,000
| +40% | +$724K |
|
52
MacroGenics
MGNX
$112M
| $2.39M | 0.43% |
80,000
+5,000
| +7% | +$150K |
|
53
Boston Scientific
BSX
$156B
| $2.38M | 0.42% |
100,000
| – | – |
|
54
Tenet Healthcare
THC
$16.3B
| $2.27M | 0.4% |
100,000
-50,000
| -33% | -$1.13M |
|
55
ADMA Biologics
ADMA
$4.12B
| $2.17M | 0.39% |
300,000
+175,000
| +140% | +$1.27M |
|
|
ADAP
56
Adaptimmune Therapeutics
ADAP
$15.6M
| $2.12M | 0.38% |
300,000
+100,000
| +50% | +$705K |
|
|
IMMU
57
DELISTED
Immunomedics Inc
IMMU
| $1.95M | 0.35% |
600,000
+375,000
| +167% | +$1.22M |
|
|
CCXI
58
DELISTED
ChemoCentryx, Inc.
CCXI
| $1.81M | 0.32% |
300,000
+150,000
| +100% | +$906K |
|
|
PRAH
59
DELISTED
PRA Health Sciences, Inc.
PRAH
| $1.7M | 0.3% |
+30,000
| New | +$1.7M |
|
60
Acadia Pharmaceuticals
ACAD
$4.38B
| $1.59M | 0.28% |
+50,000
| New | +$1.59M |
|
|
ONCE
61
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $1.5M | 0.27% |
25,000
-35,000
| -58% | -$2.1M |
|
|
EPZM
62
DELISTED
Epizyme, Inc
EPZM
| $1.48M | 0.26% |
150,000
-50,000
| -25% | -$492K |
|
63
Esperion Therapeutics
ESPR
$448M
| $1.11M | 0.2% |
+80,000
| New | +$1.11M |
|
64
MEI Pharma
MEIP
$160M
| $1.06M | 0.19% |
+600,000
| New | +$1.06M |
|
65
SCYNEXIS
SCYX
$34.9M
| $968K | 0.17% |
250,000
+125,000
| +100% | +$484K |
|
66
AbbVie
ABBV
$372B
| – | – |
0
| – | – |
|
67
Alkermes
ALKS
$4.78B
| – | – |
-30,000
| Closed | -$1.3M |
|
|
68
Baxter International
BAX
$12.7B
| – | – |
-135,000
| Closed | -$6.11M |
|
69
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| – | – |
-75,000
| Closed | -$1.27M |
|
70
Cigna
CI
$80.3B
| – | – |
0
| – | – |
|
71
Clearside Biomedical
CLSD
$28.9M
| – | – |
-75,015
| Closed | -$526K |
|
72
Cytokinetics
CYTK
$4.23B
| – | – |
-150,000
| Closed | -$1.42M |
|
73
Eli Lilly
LLY
$657B
| – | – |
0
| – | – |
|
74
Seres Therapeutics
MCRB
$166M
| – | – |
-50,000
| Closed | -$1.45M |
|
75
Novavax
NVAX
$1.21B
| – | – |
0
| – | – |
|